BMRN Biomarin Pharmaceutical
- 80.400
- +0.750+0.94%
Biomarin Pharmaceutical News
Third Point Top Buy and Sells in Q1
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.
BioMarin Pharmaceutical To Cut About 170 Employees
BioMarin Pharmaceutical To Cut About 170 Employees
Is There An Opportunity With BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) 47% Undervaluation?
Key Insights The projected fair value for BioMarin Pharmaceutical is US$152 based on 2 Stage Free Cash Flow to Equity BioMarin Pharmaceutical's US$80.50 share price signals that it might be 47% unde
BioMarin Pharmaceutical Initiated at Outperform by Evercore ISI Group
BioMarin Pharmaceutical Initiated at Outperform by Evercore ISI Group
Evercore ISI Group Initiates Coverage On Biomarin Pharmaceutical With Outperform Rating, Announces Price Target of $113
Evercore ISI Group analyst Cory Kasimov initiates coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating and announces Price Target of $113.
Biomarin Pharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 41.25% Evercore ISI Group → $113 Initiates Coverage On → Outperform 04/26/2024 40% Morgan Stanl
Biomarin Pharmaceutical(BMRN.US) Director Sells US$3.26 Million in Common Stock
$Biomarin Pharmaceutical(BMRN.US)$ Director BIENAIME JEAN JACQUES sold 40,000 shares of common stock on May 9, 10, 2024 at an average price of $81.38 for a total value of $3.26 million.Source: Announc
Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing
Jean Jacques Bienaime, Director, on May 09, 2024, sold 40,000 shares in Biomarin Pharmaceutical (BMRN) for $3,255,200. Following the Form 4 filing with the SEC, Bienaime has control over a total of 72
Form 144 | Biomarin Pharmaceutical(BMRN.US) Director Proposes to Sell 1.62 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $Biomarin Pharmaceutical(BMRN.US)$ Director BIENAIME JEAN JACQUES intends to sell 20,000 shares of its common stock on May 10, with a total market value of approximatel
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Biomarin Pharmaceutical's (NYSE:BMRN) short percent of float has risen 20.25% since its last report. The company recently reported that it has 3.69 million shares sold short, which is 1.96% of all reg
Form 144 | Biomarin Pharmaceutical(BMRN.US) Director Proposes to Sell 1.63 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 9, $Biomarin Pharmaceutical(BMRN.US)$ Director BIENAIME JEAN JACQUES intends to sell 20,000 shares of its common stock on May 9, with a total market value of approximately
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
SAN RAFAEL, Calif., May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at th
Biomarin Pharmaceutical(BMRN.US) Officer Sells US$157.27K in Common Stock
$Biomarin Pharmaceutical(BMRN.US)$ Officer Davis George Eric sold 1,850 shares of common stock on May 2, 2024 at an average price of $85.01 for a total value of $157.27K.Source: Announcement What is s
Biomarin Pharmaceutical(BMRN.US) Officer Sells US$414.55K in Common Stock
$Biomarin Pharmaceutical(BMRN.US)$ Officer Ajer Jeffrey Robert sold 5,000 shares of common stock on May 2, 2024 at an average price of $82.91 for a total value of $414.55K.Source: Announcement What is
Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing
Jeffrey Robert Ajer, Executive Vice President, Chief Commercial Officer, on May 02, 2024, sold 5,000 shares in Biomarin Pharmaceutical (BMRN) for $414,550. Following the Form 4 filing with the SEC, Aj
BioMarin Touts New Data on Voxzogo for Additional Indications
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Idexx Laboratories (IDXX) and ImmunityBio (IBRX)
BioMarin Pharmaceutical Hold Rating: Potential for Voxzogo Label Expansion Amidst Early Data and Upcoming Trials
Reported Saturday, BioMarin Presented New Data On VOXZOGO for Multiple Growth-Related Conditions in Children Presented At Pediatric Endocrine Society (PES) Annual Meeting
Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, Idiopathic Short Stature and Other Growth-Related ConditionsBioMarin-Sponsored Phase 3 Data Show No
Analysis
Price Target
No Data
